-
Assessment of the reliability of the criteria for the consistency of radioiodablation
DOI 10.31917/2304225
V.A. Solodkiy, D.K. Fomin, O.A. Borisova, Y.A. Blanter
-
Liquid biopsy in clinical oncology
DOI 10.31917/2304211
E.N. Imyanitov, E.Sh. Kuligina, G.A. Janus
-
New technologies in radiology diagnostics
DOI 10.31917/2304203
V.V. Chernobrivtseva, A.S. Misyurin
-
Thoracoscopic atypical resection of the left lung (metastasectomy) under conditions of submaximal reduction of the contralateral lung
DOI 10.31917/2303195
G.A. Baksiyan, N.G. Stepanyants, A.V. Aksenenko, D.N. Astakhov, A.A. Zavyalov.
-
Multimodal prehabilitation in patients with colorectal cancer: a systematic review
DOI 10.31917/2303187
R.A. Nurmukhametov, T.S. Dikova, V.К. Lyadov, К.А. Kulbasova, V.N. Galkin
-
Role of supportive care as an element of antitumor treatment
DOI 10.31917/2303175
М.М. Kramchaninov
-
Epigenetics: perspectives of targeted therapy
DOI 10.31917/2303170
N.M. Volkov
-
Microbiome as a therapeutic target
DOI 10.31917/2303160
F.V. Moiseenko
-
Alkalinization of the tumor microenvironment: are there prospects as a therapeutic objective?
DOI 10.31917/2303143
A.A. Bogdanov, An.A. Bogdanov, V.M. Moiseyenko
-
Vitamin C: is there a place in anticancer treatment?
DOI 10.31917/2303133
I.A. Gerk, V.M. Moiseenko
-
Iron metabolIsm and ferroptosIs as a therapeutIc target
DOI 10.31917/2303127
V.A. Chubenko
-
Multifactorial analysis of the dependence of prescribed diagnostic test systems and purchased targeted drugs on the example of lung adenocarcinoma in St.P.
DOI 10.31917/2302109
D.D. Zelikova, D.S. Yurochkin, S.E. Erdni-Garyaev, A.A. Leshkevich, Z.M. Golant, D.A. Chagin, N.M. Volkov, F.V. Moiseenko, V.M. Moiseenko
-
Possibilities of intraluminal photodynamic therapy in oncology (review)
DOI 10.31917/2302100
A.E. Akkalaeva, V.V. Klimenko, A.A. Avanesyan, V.V. Egorenkov, A.A. Bogdanov, V.M. Moiseyenko
-
The emerging field of checkpoint inhibitors
DOI 10.31917/2302093
V.A. Chubenko
-
Biomarkers predicting the effect of immunotherapy: what you need to know in practice?
DOI 10.31917/2302081
A.M. Konstantinova
-
What should we consider besides immune checkpoint drugs on the way to improvement of the efficacy?
DOI 10.31917/2302072
F.V. Moiseenko
-
Immunologic aspects of tumor biology
DOI 10.31917/2302063
N.M. Volkov
-
The most important results of clinical trials for breast cancer systemic therapy in 2021
DOI 10.31917/2301009
S.A. Tjulandin, М.В. Stenina, М.А. Frolova
-
Advances in fundamental oncology: the year 2021 update
DOI 10.31917/2301001
E.N. Imyanitov
-
Assessment of the quality of life of breast cancer patients after various types of surgical interventions
DOI 10.31917/2204298
М.А. Monogarova, Е.М. Bit-Sava, М.G. Kurbanova, А.О. Damenia, V.M. Moiseenko